Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Net Income towards Common Stockholders: 2022-2025

Historic Net Income towards Common Stockholders for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to -$47.2 million.

  • Axsome Therapeutics' Net Income towards Common Stockholders rose 26.89% to -$47.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$229.5 million, marking a year-over-year increase of 26.20%. This contributed to the annual value of -$287.2 million for FY2024, which is 20.05% down from last year.
  • According to the latest figures from Q3 2025, Axsome Therapeutics' Net Income towards Common Stockholders is -$47.2 million, which was up 1.47% from -$47.9 million recorded in Q2 2025.
  • Axsome Therapeutics' 5-year Net Income towards Common Stockholders high stood at -$11.2 million for Q1 2023, and its period low was -$98.6 million during Q4 2023.
  • Its 3-year average for Net Income towards Common Stockholders is -$61.9 million, with a median of -$64.6 million in 2024.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first soared by 71.64% in 2023, then crashed by 508.27% in 2024.
  • Axsome Therapeutics' Net Income towards Common Stockholders (Quarterly) stood at -$61.2 million in 2022, then crashed by 61.06% to -$98.6 million in 2023, then increased by 24.05% to -$74.9 million in 2024, then grew by 26.89% to -$47.2 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$47.2 million for Q3 2025, versus -$47.9 million for Q2 2025 and -$59.4 million for Q1 2025.